DAVITA INC. Q3 FY2026 earnings call

Clinical Innovation & Fluid Management:

• Implemented protocols and digital tools to manage fluid overload, resulting in a 10% improvement in optimal fluid removal and a nearly 5-pound reduction in average patient weight.
• These improvements are key drivers for continued mortality reductions and enhanced quality of life.

Expanded HD Dialyzer Rollout:

• Completed pilots in 150 centers covering >10,000 patients with >90% adoption among eligible patients.
• National rollout begins next week, targeting the vast majority of eligible patients by November.
• No material net impact on adjusted operating income expected in 2026 or 2027; positive financial impact from volume growth anticipated in late 2028.

Technology Investments:

• Invested >$1 billion recently to modernize IT platforms, yielding clinical and operational benefits.
• U.S. dialysis technology spending is higher than initially forecasted, creating a drag on full-year results.
• Growth in tech investments is expected to decelerate going forward.

Integrated Kidney Care (IKC) Progress:

• On track to outperform original annual guidance, now expecting ≥$65 million in adjusted operating income.
• Secured partnership with Humana to expand upstream CKD care to ~10,000 patients.
• Clinical interventions are reducing hospital admissions/readmissions and generating shared savings.

Policy Environment:

• CMS ESRD Final Rule includes permanent phosphate binder bundling and a 3.5% headline rate increase for LDOs, subject to quarterly downward adjustments.
• HHS Kidney Care National Plan aligns with DaVita’s goals for innovation and early intervention; company aims to collaborate on framework development.

U.S. Dialysis: Adjusted operating income was in line with expectations. Treatment volume grew 1.2% year-over-year, driven by census increases from improved mortality, offset by mistreatments. Revenue per treatment increased ~1.1% YoY due to normal rate hikes, partially offset by lower commercial mix and phosphate binder reimbursement changes. Patient care costs rose 2.4%, while G&A costs grew <2% excluding cyber expenses; technology spend grew >20%. IKC (Integrated Kidney Care): Performance exceeded expectations, delivering at least $65 million of adjusted operating income for the full year, an increase of $25 million over prior guidance. International: Adjusted operating income was $46 million, a $20 million year-over-year increase driven by Latin America growth, excluding a China-related charge.

• Full Year 2026 Adjusted Operating Income: Narrowed range to $2.175 billion – $2.25 billion.
• Full Year 2026 Adjusted EPS: Narrowed range to $14.30 – $15.20.
• Full Year 2026 Free Cash Flow: Maintained expectation of $1.0 billion – $1.25 billion.
• IKC Guidance: Raised to at least $65 million in adjusted operating income for 2026 (up $25 million from prior guidance).
• 2027 Outlook: Expect volume growth to be higher than 2026; anticipate headwinds from commercial mix/ACA but tailwinds from lower pharmaceutical costs (binders); technology spend will continue to grow but at a decelerated rate.

• Regulatory Policy Uncertainty: The new ESRD rule introduces quarterly recalculation of Tdapa add-on payments, which may decline significantly after Q1, impacting revenue stability.
• Commercial Mix Headwinds: Expiration of enhanced premium tax credits continues to reduce commercial patient mix, creating an estimated $40 million year-over-year headwind for 2026.
• Operational Variances: Mistreatment rates spiked ~20 basis points above expectations in Q3; failure to revert to normal patterns could pressure volume metrics.
• Cost Inflation: Medical supply costs and professional liability expenses were higher than anticipated in Q3, though management expects reversion to typical levels.
• Technology Spend Drag: Higher-than-forecasted IT investment creates near-term margin pressure despite long-term strategic benefits.

Q: Analyst asked about the adequacy of the finalized ESRD rate and the trajectory of Tdapa payments given the quarterly recalculation mechanism.

A: CFO stated the net full-year 2027 impact is estimated at 1.5%-2.0% growth. He clarified that while the headline rate is 3.5%, the Tdapa component (3.1%) applies only to Q1 and is expected to drop significantly in subsequent quarters, whereas the non-Tdapa portion is locked at 40 basis points for the year. This structure makes the first quarter stronger but implies weaker performance later.

Q: Analyst queried if IKC's profitability allows for aggressive expansion into new contracts and physician partnerships.

A: CEO confirmed confidence in the scalable model and clinical capabilities, stating they actively pursue more business. However, he emphasized selecting 'healthy contracts' where physicians are heavily involved and technology supports care delivery to avoid hospitalizations and control costs, rather than simply expanding volume without alignment.

Q: Analyst asked about the profitability nature of mortality improvements from expanded HD—whether extended lives result in purely additional Medicare treatments or a different demographic mix.

A: CFO explained that early data suggests younger patients earlier in their disease journey are benefiting, not just older patients adding years to existing Medicare coverage. Consequently, the revenue mix may differ from the standard 10-11% commercial split, making it too early to conclude the growth algorithm is identical to standard volume increases.

Q: Analyst sought details on the HHS Kidney Care National Plan, specifically regarding the portrayal of dialysis providers and the economic ecosystem.

A: CEO expressed frustration that the plan underappreciated DaVita’s value and scale, noting that 90% of patients are government-insured. He argued that attracting new capital requires solving the cross-subsidy dynamic between private and public payers and emphasized that competition limits stem from the difficulty of serving high-need populations, not provider operations.

Q: Analyst asked about the sizing and regulatory status of the American Kidney Fund (AKF) grants used for Premium Assistance.

A: CEO clarified that most CPA recipients use grants to maintain pre-existing commercial coverage for family protection and transplant odds, not for new commercial insurance. He noted the program has passed previous scrutiny and warned that diluting it could ironically increase government payer share and deter capital, contrary to administration goals.